Nurix Therapeutics, Inc. NRIX Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s change in deferred revenue?
- Nurix Therapeutics, Inc. (NRIX) reported change in deferred revenue of -$1.25M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s change in deferred revenue changed year-over-year?
- Nurix Therapeutics, Inc.'s change in deferred revenue increased by 87.3% year-over-year, from -$9.83M to -$1.25M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s change in deferred revenue?
- Over 2 years (2022 to 2025), Nurix Therapeutics, Inc.'s change in deferred revenue has grown at a 17.8% compound annual growth rate (CAGR), from -$26.63M to -$36.98M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.